• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Magellan Health Launches First FDA-Approved Prescription Digital Therapeutic

by HITC Staff 01/17/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

magellanhealth

Magellan Health has announced the launch of reSET therapy, a pilot initiative using the first-ever FDA cleared prescription digital therapeutic from PEAR Therapeutics to improve outcomes for individuals struggling with Substance Use Disorders (SUD) and other related conditions.

With the current challenges in our nation related to substance use, the evidence-based, non-drug treatment option presented with this approach is an opportunity to offer a practical solution to meet these complex needs and rethink the way treatment is delivered today.

The pilot program will enroll 250 patients with SUD and offer each patient a 12-week course of reSET therapy. The collaboration aims to examine patient abstinence and program retention through increased engagement and therapy adherence. The pilot will use advanced data analytics generated through the reSET therapy and accompanying clinician dashboards to more effectively provide technical support and clinical outreach to both treatment providers and their patients. Magellan will also work with PEAR to develop a series of publications highlighting the operational, economic and clinical results of this pilot program.

Magellan believes this pilot will help support the broader strategy to engage consumers in ways that match the best of new and traditional methods to drive optimal outcomes. This pilot will be important to help understand the value such FDA approved solutions bring to the healthcare market, as well as the operational requirements needed to support digital therapeutics in the future.

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), approximately 20.2 million adults have a type of SUD in the United States. Cognitive behavioral therapy, such as reSET®, is widely recognized as an important component of an overall treatment regimen for SUD. reSET® is a 12-week duration, FDA-cleared prescription digital therapeutic to be used in conjunction with standard outpatient treatment for substance use disorder related to stimulants, cannabis, cocaine, and alcohol.

This product combines patient-facing interventions and assessments via a mobile device, with clinician-facing dashboards and data analytics on the back-end. reSET® has been shown in clinical studies to increase abstinence from a patient’s substances of abuse during treatment and increase patient retention in the outpatient treatment  program. reSET® provides access to self-reported substance use, triggers, cravings and outcomes to the patient’s medical provider.

“This is an important collaboration for PEAR as we seek to bring reSET to patients with SUD,” said Corey McCann, M.D., Ph.D., president and chief executive officer of PEAR Therapeutics. “We believe that prescription digital therapeutics hold great promise in improving patient outcomes across a wide range of central nervous system disorders including psychiatry, neurology and pain, and will become a vital part of tomorrow’s treatment paradigm across all disease areas. Collaborating with a company like Magellan will help PEAR get this innovative solution to patients who need it most.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Magellan Health, PEAR Therapeutics, prescription digital therapeutic, Substance Use Disorders (SUD)

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |